生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Tuxobertinib (BDTX-189) serves as a powerful, orally administered, selective inhibitor targeting allosteric EGFR and HER2 oncogenic mutations, notably EGFR/HER2 exon 20 insertion mutants. It demonstrates dissociation constants (KDs) of 0.2, 0.76, 13, and 1.2 nM for EGFR, HER2, BLK, and RIPK2, respectively, and exhibits anticancer activity[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.78mL 0.36mL 0.18mL |
8.91mL 1.78mL 0.89mL |
17.82mL 3.56mL 1.78mL |
参考文献 |
---|